Drug Pricing Practices In Canada, Germany May Stifle Innovation – USTR Report
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.S. Trade Representative cites Canadian procedures that allow "infringing" generic drugs on the market in adding the country to its IP "watch list." The report expresses concern about Germany's development of a reference pricing system, which would lump brands with generics.
You may also be interested in...
International Rx Price Study To Be Used In Negotiations With Developed Countries
Study mandated by Medicare Rx law could be used to convince developed countries of the need to reduce price controls, Commerce Department official tells Senate subcommittees.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Deal Watch: Sanofi, Boehringer Swap Side Businesses
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.